Atea Pharmaceuticals, Inc.
$5.71
▲
1.95%
2026-04-21 05:30:00
ateapharma.com
NMS: AVIR
Explore Atea Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$457.32 M
Current Price
$5.71
52W High / Low
$6.45 / $2.46
Stock P/E
—
Book Value
$3.52
Dividend Yield
—
ROCE
-65.67%
ROE
-44.34%
Face Value
—
EPS
$-1.94
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
0.16
Debt / Equity
0.31
Current Ratio
7.82
Quick Ratio
7.82
Forward P/E
-4.09
Price / Sales
—
Enterprise Value
$150.75 M
EV / EBITDA
-0.84
EV / Revenue
—
Rating
None
Target Price
$8.83
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 2. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 3. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 4. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 5. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
| 6. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 7. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -54.93 M | -45.57 M | -41.34 M | -39.04 M | -39.03 M |
| Net Profit | -44.87 M | -42.05 M | -37.16 M | -34.27 M | -33.54 M |
| EPS in Rs | -0.56 | -0.53 | -0.47 | -0.43 | -0.42 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -180.89 M | -192.95 M | -164.16 M | -130.65 M |
| Net Profit | -158.35 M | -168.38 M | -135.96 M | -115.91 M |
| EPS in Rs | -1.99 | -2.11 | -1.71 | -1.45 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 315.22 M | 464.67 M | 594.97 M | 666.71 M |
| Total Liabilities | 39.78 M | 25.8 M | 39.78 M | 26.14 M |
| Equity | 275.43 M | 438.87 M | 555.19 M | 640.57 M |
| Current Assets | 310.99 M | 462.36 M | 590.46 M | 660.92 M |
| Current Liabilities | 39.78 M | 18.6 M | 32.38 M | 18.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -132.03 M | -135.5 M | -85.39 M | -120.98 M |
| Investing CF | 188.79 M | 56.1 M | 40.3 M | -455.41 M |
| Financing CF | -25.75 M | 0.27 M | 0.26 M | 0.37 M |
| Free CF | -132.03 M | -135.5 M | -85.39 M | -122.92 M |
| Capex | — | — | — | -1.94 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -23.85% | -17.3% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.